{"doi":"10.1016/j.jaci.2024.09.019","title":"Clinical effectiveness and safety of dupilumab in patients with chronic obstructive pulmonary disease: A 7-year population-based cohort study","abstract":null,"journal":"Journal of Allergy and Clinical Immunology","year":2025,"id":645318,"datarank":0.4335557636844247,"base_score":2.8903717578961645,"endowment":2.8903717578961645,"self_citation_contribution":0.4335557636844247,"citation_network_contribution":0.0,"self_endowment_contribution":0.4335557636844247,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":17,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":305925,"name":"Yohannes Tesfaigzi","orcid":"0000-0002-3997-5839","position":1,"is_corresponding":false},{"id":1680261,"name":"Gin-Yi Lee","orcid":null,"position":2,"is_corresponding":false},{"id":1097878,"name":"Yi-Hsuan Chen","orcid":"0000-0002-6788-4264","position":3,"is_corresponding":false},{"id":25033,"name":"Scott T. Weiss","orcid":"0000-0001-7196-303X","position":4,"is_corresponding":false},{"id":1607198,"name":"Kevin Sheng-Kai Ma","orcid":null,"position":5,"is_corresponding":false},{"id":1680260,"name":"Chuan-Yen Sun","orcid":"0009-0001-7969-4679","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Clinical effectiveness and safety of dupilumab in patients with chronic obstructive pulmonary disease: A 7-year population-based cohort study","abstract":"<h4>Background</h4>Previous randomized controlled trials have established the efficacy of dupilumab among patients with chronic obstructive pulmonary disease (COPD) treated with triple therapy over 52 weeks of follow-up.<h4>Objective</h4>This population-based cohort study aimed to explore the long-term safety and effectiveness of dupilumab in patients with COPD.<h4>Methods</h4>The study included US patients with COPD who were seen between April 2017 and August 2024. Patients initiating dupilumab and therapies that incorporated long-acting β<sub>2</sub>-agonist (LABA) inhalers were included. Patients with asthma or lung cancer were excluded. The risk of outcomes occurring after initiation of dupilumab versus LABA-containing therapies was measured. For detailed methods, please see the Methods section in this article's Online Repository at www.jacionline.org.<h4>Results</h4>A total of 1521 dupilumab initiators and 1521 propensity score-matched patients who were receiving LABA-based therapies were included. Receiving dupilumab was associated with lower all-cause mortality (hazard ratio [HR] = 0.53, 95% CI = 0.43-0.65), fewer emergency department visits (HR = 0.78, 95% CI = 0.69-0.89), and lower acute exacerbation rates (HR = 0.59, 95% CI = 0.53-0.65). Dupilumab was also associated with reductions in the requirement for short-acting β<sub>2</sub>-agonists (HR = 0.48, 95% CI = 0.43-0.52) and short-acting muscarinic antagonists (HR = 0.43, 95% CI = 0.37-0.49) for symptom control. Additionally, dupilumab decreased rates of subsequent pneumonia (HR = 0.65, 95% CI = 0.50-0.86), and COPD-relevant comorbidities, including new-onset heart failure (HR = 0.69, 95% CI = 0.53-0.90) and new-onset anxiety (HR = 0.70, 95% CI =0.53-0.93).<h4>Conclusions</h4>In patients with COPD, dupilumab was associated with a lower mortality rate, fewer emergency department visits, and a reduced risk of acute exacerbations, respiratory symptoms, and respiratory infections. More studies are needed to validate the efficacy of dupilumab among patients with COPD of various severities.","is_dataset_classified":null,"base_score":2.833213344056216,"endowment":2.833213344056216,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39368553","pmcid":null,"openalex_id":"https://openalex.org/W4403097813","authors":[],"funders":[{"funder_name":"NHLBI NIH HHS","grant_id":"R01 HL140839","title":null},{"funder_name":"NHLBI NIH HHS","grant_id":"R56 HL068111","title":null},{"funder_name":"NHLBI","grant_id":"","title":null}],"total_grants":3,"fwci":5.3975,"citation_percentile":0.96457272,"influential_citations":0,"citation_trend":[{"year":2024,"count":2},{"year":2025,"count":11},{"year":2026,"count":3}],"oa_status":"closed","license":"http://www.elsevier.com/open-access/userlicense/1.0/","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0091674924010212?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0091674924010212?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.jaci.2024.09.019","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39368553","host_type":"repository"}],"fields_of_study":["Chronic Obstructive Pulmonary Disease (COPD) Research","Cancer Immunotherapy and Biomarkers","Pediatric health and respiratory diseases","Humans","Pulmonary Disease, Chronic Obstructive","Antibodies, Monoclonal, Humanized","Male","Female","Aged","Middle Aged","Cohort Studies","Adrenergic beta-2 Receptor Agonists","Treatment Outcome"],"mesh_terms":["Aged","Female","Humans","Male","Middle Aged","Cohort Studies","Treatment Outcome","Pulmonary Disease, Chronic Obstructive","Adrenergic beta-2 Receptor Agonists","Antibodies, Monoclonal, Humanized"],"keywords":["Dupilumab","Medicine","Pulmonary disease","Cohort","COPD","Population","Cohort study","Internal medicine","Environmental health","Asthma","Acute Exacerbations","Anti–il-13 Receptor","Anti–il-4 Receptor"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-09T04:45:02.096531Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}